Median survival rates in long-acting selleckchem Cabozantinib octreotide [Sandostatin LAR], TACE, multimodal therapy and palliative care were 31.4, 37.3, 40.2 and 15.1 months respectively (Table (Table2).2). Although survival rates of patients with “active” treatment (long-acting octreotide [Sandostatin LAR], TACE or multimodal therapy) were more than twice as long as of patients who received only palliative care this difference was not significant. Survival rates of patients with various active treatment modalities did not differ significantly. Table 2 Patient survival according to BCLC stage and treatment The 1 year survival rate in the long-acting octreotide [Sandostatin LAR] group was 64% and in patients who received multimodal therapy, TACE, and palliative care 86%, 80% and 53%, respectively.

The 2 year survival rate in the long-acting octreotide [Sandostatin LAR] group was 55% and in patients who received multimodal therapy, TACE, and palliative care 82%, 60% and 29%, respectively. Patients with BCLC Stage B 55 patients were classified as BCLC stage B. These patients received long-acting octreotide [Sandostatin LAR] (n = 14 [25.4%]), TACE (n = 9 [16.4%]), multimodal therapy as defined above (n = 10 [18.2%]) and palliative care (n = 22 [40.0%]), respectively. Median Survival (Figure (Figure22) Figure 2 Patients with hepatocellular carcinoma and BCLC stage B. Median survival rates in long-acting octreotide [Sandostatin LAR], TACE, multimodal therapy and palliative care were 22.4, 22.0, 35.5 and 2.9 months respectively. Median survival among patients … Overall median survival was 15.

1 months. Median survival rates of the group receiving long-acting octreotide [Sandostatin LAR], TACE, multimodal therapy and palliative care were 22.4, 22.0, 35.5 and 2.9 months, respectively (Table (Table2).2). Survival rates of patients with “active” treatment (long-acting octreotide [Sandostatin LAR], TACE or multimodal therapy) were significantly higher than of patients who received palliative care only (log rank test: P = 0.00043, P = 0.00151, P = 0.00005). Median survival among patients with various “active” treatment forms did not show significant differences (log rank test: P > 0.05). The 1 year survival rate in the long-acting octreotide [Sandostatin LAR] group was 64% and in patients who received multimodal therapy, TACE, and palliative care 90%, 78% and 23%, respectively.

The 2 year survival rate in the long-acting octreotide [Sandostatin LAR] group was 36% and in patients who received multimodal therapy, TACE, and palliative care 80%, 34% and 5%, respectively. Discussion In the present paper we studied retrospectively the influence of octreotide monotherapy (long-acting AV-951 octreotide [Sandostatin LAR]) on survival of patients with hepatocellular carcinoma and compared it to BCLC stage-matched patients who received either TACE, multimodal therapy or palliative care only.